Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Luciferase-IN-1
Cat. No.:
OB0225LY-0245
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Luciferase-IN-1 is a specific compound used to inhibit fluoresceinase activity.
Synonym:
10205-56-8; 4-(1,3-Benzothiazol-2-yl)-N, N-dimethylaniline; Benzenamine, 4-(2-benzothiazolyl)-N, N-dimethyl-; 4-(Benzo[d]thiazol-2-yl)-N, N-dimethylaniline; (4-Benzothiazol-2-yl-phenyl)-dimethyl-amine; 2-(4'-Dimethylaminophenyl)benzothiazole
CAS No.:
10205-56-8
Compound CID:
95755
Formula:
C15H14N2S
Formula Weight:
254.35
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Luciferase-IN-1 can be used to study the regulatory mechanisms of cell signaling and gene expression.
Library Information
Targets:
Reactive oxygen species
Pathways:
Metabolism; Immunology/Inflammation; NF-κB; Microbiology/Virology
Plate Number:
AOCL-4
Plate Location:
a10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
9.0 mg/mL; 35.4 mM
